Federal Register / Vol. 76, No. 51 / Wednesday, March 16, 2011 / Notices 14401 

about one quarter of people who have a 

PE. 

The Division of Blood Disorders 

submitted questions to the 2007 

HealthStyles survey to determine the 

public’s knowledge of DVT, its common 

symptoms, and risk factors. Although 

over 60% of respondents identified pain 

and swelling as symptoms, 60% did not 

identify tenderness (often the first sign 

of DVT) as a symptom. Only 38% of 

respondents knew that a DVT was a 

blood clot in a vein, and most could not 

identify common risk factors for DVT 

such as sitting for a long period of time 

(e.g., during air travel); having a leg or 

foot injury; having a family member 

who has had a DVT; taking birth control 

pills; or getting older; and certain 

groups could not identify risk factors 

that specifically applied to their risk. 

The results of this survey demonstrates 

the need for greater awareness of DVT, 

and its risk factors and the data show 

that there are many opportunities to 

develop audience specific messages that 

are age specific and culturally 

appropriate. 

Much of the morbidity and mortality 

associated with DVT/PE could be 

prevented with early and accurate 

diagnosis and management. DVT/PE is 

preventable. It is important for people to 

be able to recognize the signs and 

symptoms and know when to seek care 

and available treatment. Individuals, 

families, and their support communities 

can reduce their risk by understanding 

DVT/PE and its risk factors. DVT/PE 

affects people of all races and ages. 

Many of the acquired risks such as 

obesity, advanced age, air travel, 

chronic diseases, cancer, and 

hospitalization are increasing in the 

United States, and we can expect to see 

increasing numbers of people affected 

by DVT/PE. 

The CDC’s Division of Blood 

Disorders will conduct focus groups to 

develop messaging concepts that will be 

used in a public awareness campaign to 

build knowledge and awareness of DVT/ 

PE, increase recognition of the 

symptoms and risk factors for DVT/PE, 

and empower people to take action. 

The project will address these 

objectives in two stages: In the first stage 

the Contractor selected will conduct 

eight (8) formative focus groups with 

nine (9) participants in each focus group 

to explore consumer knowledge, 

attitudes, and beliefs (KABs) toward 

DVT. It is estimated that 144 

respondents will have to be screened in 

order to recruit 72 focus group 

participants. Message concepts will be 

developed from insights emerging from 

this exploratory research phase. The 

Contractor will conduct eight (8) focus 

groups with nine (9) participants in 

each focus group during the second 

stage to test the message concepts and 

identify possible ways to present the 

messages. It is estimated that 144 

respondents will have to be screened in 

order to recruit 72 focus group 

participants. The informed consent will 

take approximately 6 minutes to 

complete, for a total burden of 7 hours. 

The Contractor selected will work 

with CDC to identify and recruit focus 

group participants. Formative research 

participants will include adults (aged 

25–64) who have been hospitalized in 

the last year and seniors (aged 65–80). 

Message testing participants will 

include adults (aged 25–64) who have 

been hospitalized in the last year and 

seniors (aged 65–80). Participants will 

be recruited to participate in one of 

sixteen in-person focus groups that will 

be conducted in the following cities: 

• Atlanta, Baltimore, Pittsburgh, and 

Tampa (formative research task), and 

• Atlanta, Baltimore, Pittsburgh, and 

Tampa (message testing task) 

There are no costs to the respondents 

other than their time. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondent Form name Number of 

respondents 

Number 

responses per 

respondent 

Average 

burden per 

response (in 

hours) 

Total burden 

hours 

Seniors (65–80) ................................

Adults (25–64) recently hospitalized 

Formative research stage: Participant Screener and Recruitment 

Script.

144 1 5/60 12 

Seniors (65–80) ................................

Adults (25–64) recently hospitalized 

Message testing stage: Re-screener 144 1 9/60 22 

Seniors (65–80) ................................

Adults (25–64) recently hospitalized 

Formative Research stage: Moderator’s Guide.72 1 1.5 108 

Seniors (65–80) ................................

Adults (25–64) recently hospitalized 

Formative Research stage: Informed 

Consent.

72 1 6/60 7 

Seniors (65–80) ................................

Adults (25–64) recently hospitalized 

Message testing stage: Moderator’s 

Guide.

72 1 1.5 108 

Seniors (65–80) ................................

Adults (25–64) recently hospitalized 

Message testing stage: Informed 

Consent.

72 1 6/60 7 

Total ........................................... ........................................................... ........................ ........................ ........................ 264 

Dated: March 10, 2011. 

Carol E. Walker, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2011–6107 Filed 3–15–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30-Day–11–0338] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) publishes a list of 

information collection requests under 

review by the Office of Management and 

Budget (OMB) in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

chapter 35). To request a copy of these 

requests, call the CDC Reports Clearance 

Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written 

comments to CDC Desk Officer, Office of 

Management and Budget, Washington, 

DC or by fax to (202) 395–5806. Written 

comments should be received within 30 

days of this notice. 


jlentini on DSKJ8SOYB1PROD with NOTICES
14402 Federal Register / Vol. 76, No. 51 / Wednesday, March 16, 2011 / Notices 

Proposed Project 

Annual Submission of the Ingredients 

Added to, and the Quantity of Nicotine 

Contained in, Smokeless Tobacco 

Manufactured, Imported, or Packaged in 

the U.S. (OMB No. 0920–0338, exp. 4/ 

30/2011)—Extension—Office on 

Smoking and Health, National Center 

for Chronic Disease Prevention and 

Health Promotion (NCCDPHP), Centers 

for Disease Control and Prevention 

(CDC). 

Background and Brief Description 

The Centers for Disease Control and 

Prevention (CDC), Office on Smoking 

and Health (OSH) has the primary 

responsibility for the Department of 

Health and Human Services (HHS) 

smoking and health program. HHS’s 

overall goal is to reduce death and 

disability resulting from the use of 

smokeless tobacco products and other 

forms of tobacco use through programs 

of information, education and research. 

Since 1994, as required by the 

Comprehensive Smokeless Tobacco 

Education Act of 1986 (CSTHEA, 15 

U.S.C. 4401 et seq., Public Law 99–252), 

CDC has collected information about the 

ingredients used in smokeless tobacco 

products and their nicotine content. 

Respondents are commercial smokeless 

tobacco product manufacturers, 

packagers, or importers (or their 

representatives), who are required by 

the CSTHEA to submit ingredient 

reports to HHS on an annual basis. 

Respondents are not required to 

submit specific forms; however, they are 

required to meet reporting guidelines 

and to submit the ingredient report by 

chemical name and Chemical Abstract 

Service (CAS) Registration Number, 

consistent with accepted reporting 

practices for other companies currently 

required to report ingredients added to 

other consumer products. Typically, 

respondents submit a summary report to 

CDC with the ingredient information for 

multiple products, or a statement that 

there are no changes to their previously 

submitted ingredient report. 

Ingredient reports for new products 

are due at the time of first importation. 

Thereafter, ingredient reports are due 

annually on March 31. Information is 

submitted to OSH by mailing a written 

report on the respondent’s letterhead, by 

CD, three-inch floppy disk, or thumb 

drive. Electronic mail submissions are 

not accepted. 

Upon receipt and verification of the 

annual ingredient and nicotine data 

reports, OSH issues a Certificate of 

Compliance to the respondent. OSH also 

uses the information to report to the 

Congress (as deemed appropriate) 

discussing the health effects of these 

ingredients. 

In this Extension request, there are no 

changes to the estimated number of 

respondents, the estimated burden per 

response, or the information collection 

methods. There are no costs to 

respondents other than their time. The 

total estimated annualized burden hours 

are 18,843. 

ESTIMATED ANNUALIZED BURDEN HOURS

Type of respondents Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Smokeless Tobacco Manufacturers, Packagers, and Importers ................................................ 11 1 1,713 

Dated: March 10, 2011. 

Carol E. Walker, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2011–6106 Filed 3–15–11; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[Docket No. CDC–2011–0002] 

Draft Action Plan—A Public Health 

Action Plan To Combat Antimicrobial 

Resistance 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (DHHS). 

ACTION: Notice of availability and 

request for public comment. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS) is publishing 

this notice requesting public comment 

on the draft A Public Health Action Plan 

to Combat Antimicrobial Resistance. 

HHS/CDC is publishing this notice on 

behalf of the HHS Interagency Task 

Force on Antimicrobial Resistance. The 

draft Action Plan and supporting 

documents can be found at http:// 

www.regulations.gov. 

DATES: Written comments must be 

received on or before April 15, 2011. 

Comments received after April 15, 2011 

will be considered to the fullest extent 

possible. 

ADDRESSES: Written comments may be 

submitted to the following address: 

Centers for Disease Control and 

Prevention, National Center for 

Emerging and Zoonotic Infectious 

Diseases, Division of Healthcare Quality 

Promotion, Office of Antimicrobial 

Resistance, Attn: Antimicrobial 

Resistance Action Plan, Docket No. 

CDC–2011–0002, 1600 Clifton Rd., NE., 

Mailstop A–07, Atlanta, Georgia 30333. 

You may also submit written 

comments electronically to: http:// 

www.regulations.gov. All comments 

received will be posted publicly without 

change, including any personal or 

proprietary information provided. To 

download an electronic version of the 

plan, access http://www.regulations.gov. 

Written comments, identified by 

Docket No. CDC–2011–0002 will be 

available for public inspection Monday 

through Friday, except for legal 

holidays, from 9 a.m. until 5 p.m., 

Eastern Daylight Time, at 1600 Clifton 

Road, NE., Atlanta, Georgia 30333. 

Please call ahead to (404) 639–4000 and 

ask for a representative from the Office 

of Antimicrobial Resistance to schedule 

your visit. Comments may also be 

viewed at http://www.regulations.gov. 

FOR FURTHER INFORMATION CONTACT: 

Rachel Wolf, Centers for Disease Control 

and Prevention, National Center for 

Emerging and Zoonotic Infectious 

Diseases, Division of Healthcare Quality 

Promotion, Office of Antimicrobial 

Resistance; 1600 Clifton Road, NE., 

Mailstop A–07, Atlanta, Georgia 30333, 

(404) 639–4000. 

SUPPLEMENTARY INFORMATION: The HHS 

Interagency Task Force on 

Antimicrobial Resistance (hereafter 

referred to as the Task Force) was 

created in 1999 to coordinate the 

activities of Federal agencies in 

addressing antimicrobial resistance (AR) 

in recognition of the increasing 

importance of AR as a public health 

threat. The Task Force is co-chaired by 


jlentini on DSKJ8SOYB1PROD with NOTICES